| Literature DB >> 29938690 |
De-Bao Liu1, Cong Sui1, Ting-Ting Wu2, Lian-Zhong Wu2, You-Yu Zhu2, Zhen-Hua Ren2,3.
Abstract
BACKGROUND To investigate the effect of the BMP/Smad signaling pathway on fracture healing and osteogenic ability in senile osteoporotic fracture on humans and rats. MATERIAL AND METHODS Sixty-two patients and well-matched normal controls were enrolled for clinical observation. A rat model of senile osteoporotic fracture was established. Serum BMP2 and Smad4 levels, as well as alkaline phosphatase (ALP) activity, were detected by ELISA. Fracture healing was observed by X-ray radiography and bone formation was analyzed by micro-CT. RESULTS Serum BMP2 and Smad4 levels in patients with senile osteoporotic fracture were significantly lower than those in normal controls (all P<0.01). BMP2 was highly positively correlated with Smad4 in patients with senile osteoporotic fracture (r=0.738). Compared with patients with low serum BMP2 and Smad4 levels, visual analog scale scores decreased, bone mineral density (BMD) increased, and duration of fracture healing was shortened in patients with high levels (all P<0.05). Compared with the Model group, serum BMP2 and Smad4 levels increased, fracture healing was improved, BMD, trabecular bone volume (TBV), tissue volume (TV), bone volume fraction (BV/TV), mean trabecular thickness (Tb. Th), and mean number of trabecular bone (Tb. N) were increased, and ALP activity increased in the BMP2 overexpression group (all P<0.05), while each index in the NC group showed no statistical difference relative to rats in the Model group (all P>0.05). CONCLUSIONS BMP2 overexpression can promote fracture healing and osteogenic ability in senile osteoporotic fractures through activating the BMP/Smad signaling pathway.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29938690 PMCID: PMC6050999 DOI: 10.12659/MSM.905958
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Comparison in general information between the case group and the control group.
| Variables | Case group (n=628) | Control group (n=62) | t/χ2 | |
|---|---|---|---|---|
| Average age | 69.1±8.3 | 67.4±7.9 | 0.93 | 0.351 |
| Gender (male/female) | 32/30 | 35/27 | 0.15 | 0.696 |
| Smoking history (yes/no) | 24/36 | 23/49 | 0.31 | 0.578 |
| Drinking history (yes/no) | 28/34 | 29/33 | 0.16 | 0.686 |
| Bone mineral density (kg/cm2) | 24.84±1.08 | 25.42±0.86 | 3.25 | 0.078 |
| Educational degree | 1.26 | 0.885 | ||
| Junior middle school | 17 | 18 | ||
| Junior and high school | 32 | 33 | ||
| University and above | 13 | 11 | ||
| Diet | 0.91 | 0.340 | ||
| Low calcium | 23 | 18 | ||
| Normal | 39 | 44 |
Figure 1BMP2 and Smad4 levels in the case group and the control group. (A) BMP2 level in the case group and the control group; (B) Smad4 level in the case group and the control group. ** Compared with the control group, P<0.01; BMP2 – bone morphogenetic protein-2.
Figure 2Correlation analysis of BMP2 and Smad4 levels in the case group. BMP2 – bone morphogenetic protein-2.
Correlation of serum BMP2 and Smad4 levels with fracture healing in patients.
| Indicators | BMP2 | Smad4 | ||
|---|---|---|---|---|
| High level | Low level | High level | Low level | |
| Pain score | 1.04±0.15 | 3.63±0.36 | 1.57±1.10 | 3.09±1.11 |
| Bone mineral density (kg/cm2) | 2.67±0.12 | 0.73±0.08 | 2.26±0.82 | 1.14±0.82 |
| Duration of fracture healing (d) | 43.07±3.18 | 49.86±4.72 | 44.37±4.59 | 48.58±5.14 |
Compared with the same indicator at a high level, P<0.05;
BMP2 – bone morphogenetic protein-2
Bone mineral density measurement results in experimental rats.
| Month age | Case | Bone mineral density (g/cm2) |
|---|---|---|
| 12 months old | 10 | 0.189±0.0058 |
| 22 months old | 10 | 0.165±0.0064 |
Compared with the rats in the age of 12 months, P<0.05.
Figure 3Serum (A) BMP2 and (B) Smad4 expressions in rats of each group. ** Compared with the Model group, P<0.01; BMP2 – bone morphogenetic protein-2.
Figure 4Observation of callus formation in rats of each group by X-ray radiography.
Changes in fracture healing-related indexes in rats of each group.
| Indexes | Model | NC | BMP2 |
|---|---|---|---|
| BMD (mg/mm) | 427.31±28.75 | 425.72±27.96 | 469.39±30.48 |
| TBV (mm3) | 24.42±3.61 | 22.87±3.58 | 41.05±4.02 |
| TV (mm3) | 29.87±3.52 | 31.16±3.84 | 53.92±5.17 |
| BV/TV (%) | 58.09±5.65 | 57.74±5.83 | 71.58±6.41 |
| Tb. Th (mm) | 0.59±0.04 | 0.56±0.05 | 0.78±0.07 |
| Tb. N (mm-1) | 1.12±0.23 | 1.09±0.21 | 1.42±0.26 |
BMD – bone mineral density; TBV – trabecular bone volume; TV – tissue volume; BV/TV – bone volume fraction; Tb. Th – mean trabecular thickness; Tb. N – mean number of trabecular bone; NC – negative control; BMP2 – bone morphogenetic protein-2.
Figure 5Serum ALP activity in rats of each group. * Compared with the Model group, P<0.05; ALP – alkaline phosphatase.